Mirum Pharmaceuticals AG
Mirum Pharmaceuticals is a biotech company launched in San Francisco with its European headquarters located in Basel. Mirum's pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of rare liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, Mirum advances its lead candidate, maralixibat for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues.